<DOC>
	<DOC>NCT03103282</DOC>
	<brief_summary>The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.</brief_summary>
	<brief_title>Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery.</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Main Inclusion criteria: 1. Male or female patient ≥18 years old 2. Subject undergoing elective carotid endarterectomy either with patch reconstruction or eversion technique 3. Subject who is able to give voluntary, written informed consent to participate in this clinical study and from whom consent has been obtained 4. Subject, who, in the opinion of the Clinical Investigator, is able to understand this clinical study, cooperate with the study procedures and is willing to return for the required posttreatment followup Main exclusion criteria: 1. Presence or sequelae of coagulation disorder 2. Known allergy or hypersensitivity to any component of PuraStat® 3. Concurrent participation in another clinical trial with a medical device or a medicinal product 4. Pregnant or interested in becoming pregnant during the duration of the study, or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>